慢性肾病患者对比剂肾病的研究进展

Research progress in contrast-induced nephropathy for patients with chronic kidney disease

随着临床对比剂应用的增加,对比剂肾病(contrast-induced nephropathy,CIN)的发病率也随之升高,CIN为血管内应用对比剂后出现的一过性肾功不全。CIN发生率的增加导致住院时间延长、血液透析治疗的需要增加、主要不良心血管事件发生率增加。据统计,肾功能正常的患者CIN的发病率很低,只有不到2%,但对于合并慢性肾病(chronic kidney disease,CKD)的患者,其发病率则上升至12%~27%。然而,目前对于CIN没有特异性治疗措施,临床上以预防为主。

With the increase of clinical contrast agents, the incidence of contrast-induced nephropathy （CIN） is enhanced. Contrast nephropathy is a transient renal dysfunction after contrast agents in the blood vessel. The augment in the incidence of contrast induced nephropathy results in longer hospital stay, increased need for hemodialysis treatment, and an increased incidence of major adverse cardiovascular events. According to statistics, the incidence of CIN in patients with normal renal function is very low, less than 2%.However, for patients with chronic kidney disease （CKD）, the incidence increases to 12%–27%. However, there is no specific treatment for contrast nephropathy, which is mainly based on prevention.